Interleukin 28B Gene Variation at rs12979860 Determines Early Viral Kinetics During Treatment in Patients Carrying Genotypes 2 or 3 of Hepatitis C Virus

Abstract

Single-nucleotide polymorphisms upstream of the interleukin 28B (interferon λ3) gene (IL28B) strongly influence treatment efficacy in patients carrying hepatitis C virus (HCV) of genotype 1. In patients receiving 12 or 24 weeks of interferon-ribavirin therapy for infection with genotype 2 or 3 (n = 341), we found that rs12979860 strikingly determined the first phase of viral elimination (P < .001). In patients treated for 24 weeks, rs12979860 also predicted the rate of sustained virologic response (P = .02), especially among those with high baseline HCV RNA levels (P = .002) or older than 45 years (P = .01). Patients carrying CC(rs12979860) had higher baseline HCV RNA levels (P < .001) and did not, when treated for 12 weeks, achieve sustained virologic response more often than those carrying CT(rs1297986) or TT(rs1297986). The results indicate that IL28B gene testing may identify patients carrying genotype 2 or 3 who could benefit from extended treatment.

Association of IL28B single nucleotide polymorphism rs8099917 with response to treatment in genotype 3 HCV-infected patients from India

“…Subsequent studies have successfully validated these findings in both genotype 1 19 and genotype2 and 3 infected patients from different ethnic groups. [20][21][22] There are differences in the strength of the association as well as predicted relationship to SVR depending on the viral genotype. Association studies on genotypes 2 and 3 have shown inconsistent results so far.…”

Cost-Effectiveness of <b><i>IL28&#x0392;</i></b> Genotype-Guided Protease Inhibitor Triple Therapy versus Standard of Care Treatment in Patients with Hepatitis C Genotypes 2 or 3 Infection

“…The decision tree in Figure 1 models the health state pathways (and the corresponding costs and transition probabilities) for the SOC therapy regimens implemented in the studies by Sarrazin (2011) [7] and Lindh (2011) [14]. For modeling the Sarrazin study, the treatment arms were stratified by HCV genotype, while the treatment arms modeling the study by Lindh were stratified by the duration of therapy, which was either 12 or 24 weeks.…”

Hepatitis C in Argentina: epidemiology and treatment

“…Pretreatment variables that predict SVR in HCV-G3 patients are fibrosis stage (≤ F2), age less than 40 years, white ethnicity, female sex, basal viral load below 400,000 IU/mL, weight less than 85 kg, coffee consumption, and absence of steatosis. As in G2, the IFNL3 polymorphism seems to only predict RVS in patients who do not achieve RVR 52,54…”